Relmada Therapeutics Stock (NASDAQ:RLMD)
Previous Close
$2.21
52W Range
$0.24 - $3.98
50D Avg
$1.61
200D Avg
$0.75
Market Cap
$69.70M
Avg Vol (3M)
$733.55K
Beta
0.92
Div Yield
-
RLMD Company Profile
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.